Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Blais

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Drug Safety|July 20, 2015
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials DatabasePaul B Watkins, James H Lewis, Neil Kaplowitz, et al.
Kidney International Reports|November 17, 2017
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical TrialMaria V Irazabal, Jaime D Blais, Ronald D Perrone, et al.
Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 10, 2017
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trialEmilie Cornec-Le Gall, Jaime D Blais, Maria V Irazabal, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Drug Safety|July 20, 2015
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials DatabasePaul B Watkins, James H Lewis, Neil Kaplowitz, et al.
Kidney International Reports|November 17, 2017
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical TrialMaria V Irazabal, Jaime D Blais, Ronald D Perrone, et al.
Kidney International|March 23, 2019
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney diseaseRon T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 10, 2017
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trialEmilie Cornec-Le Gall, Jaime D Blais, Maria V Irazabal, et al.
Pageof 6